Destiny, SporeGen collaborate on COVID-19 prevention spray
Development of SPOR-COV is supported by a grant from Innovate UK
Read More
Tag: destiny pharma
Destiny Pharma’s novel antibiotic asset clears safety review
Independent Data Monitoring Committee recommended continuing Phase IIb study
Read More
Destiny Pharma to get £1.6M grant for AMR
Destiny Pharma has been awarded a significant new grant funding up to £1.6 million, under the new UK-China antimicrobial resistance (AMR) programme.
Read More
Destiny Pharma listed on London Stock Exchange
Brighton, UK-based Destiny Pharma has been successfully listed shares on London Stock Exchange with a market capitalisation of £65.4 million, marking the second biotech company to float this year in the UK.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
